Organization · Venture Capital
Syridex Bio
Syridex Bio is a life sciences venture creation firm based in Princeton, NJ, focused on building companies that address health inequities for underserved communities. They invest in innovative therapies and digital health solutions.
Overview
What Syridex Bio does
What Syridex Bio is
Syridex Bio is a life sciences venture creation firm based in Princeton, NJ, focused on building companies that address health inequities for underserved communities. They invest in innovative therapies and digital health solutions.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find Syridex Bio elsewhere
Open the official website or a supported primary organization account.
Capability profile
Syridex Bio as a funder
Investment thesis
Syridex Bio focuses on creating and launching life-sciences companies that develop innovative, accessible solutions for diseases disproportionately impacting underserved communities.
Focus narrative
Syridex Bio invests in life sciences companies that develop innovative solutions for diseases disproportionately affecting underserved populations. Their approach includes identifying emerging fields of science and medicine, conducting rigorous diligence to validate opportunities, and creating agile, well-capitalized companies to ensure health innovation is accessible and equitable.
Value beyond capital
Syridex Bio provides significant value to its portfolio companies through its expertise in life sciences, regulatory affairs, and commercialization. The firm leverages its strong operational bench to guide companies from formation through to market entry, ensuring that health innovations are not only scientifically sound but also accessible to the communities that need them most.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 2
Portfolio context
Antigenix Therapeutics: A preclinical oncology company developing next-generation antibody-drug conjugates (ADCs) for treating aggressive cancers, including triple-negative breast cancer. Qunova: A digital health company that is creating an AI-driven platform to model, simulate, and optimize population health strategies.
Common questions
What to know about Syridex Bio
Upseed classifies Syridex Bio under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.